Summary: Using metacognitive therapy to reduce rumination can help relieve symptoms of depression, a new study reports.
Source: Norwegian University of Science and Technology.
Teaching patients not to ruminate offers important coping skill for depression.
Depressed individuals “don’t need to worry and ruminate,” says Professor Roger Hagen, at the Norwegian University of Science and Technology’s (NTNU) Department of Psychology. “Just realizing this is liberating for a lot of people.”
Hagen and NTNU colleagues Odin Hjemdal, Stian Solem, Leif Edward Ottesen Kennair and Hans M. Nordahl have recently published a scientific paper on the treatment of depression using metacognitive therapy (MCT).
The study shows that learning to reduce rumination is very helpful for patients with depressive symptoms.
Some people experience their persistent ruminative thinking as completely uncontrollable, but individuals with depression can gain control over it,” says Hagen.
The patients involved in the study were treated over a ten-week period. After six months, 80 per cent of the participants had achieved full recovery from their depression diagnosis.
“The follow-up after six months showed the same tendency,” says Hagen.
Separating thoughts and reality
Today, medications and cognitive-behavioural therapy (CBT) are the recommended treatments for depression and anxiety. In CBT, patients engage in analysing the content of their thoughts to challenge their validity and reality test them.
Metacognitive therapy, by contrast, focuses on lessening the ruminative process.
“Anxiety and depression give rise to difficult and painful negative thoughts. Many patients have thoughts of mistakes, past failures or other negative thoughts. Metacognitive therapy addresses thinking processes,” Hagen says, rather than the thought content.
Patients with depression “think too much, which MCT refers to as ‘depressive rumination.’ Rather than ruminating so much on negative thoughts, MCT helps patients to reduce negative thought processes and get them under control,” he says.
By becoming aware of what happens when they start to ruminate, patients learn to take control of their own thoughts.
As Hagen explains, “Instead of reacting by repeatedly ruminating and thinking ‘how do I feel now?’ you can try to encounter your thoughts with what we call ‘detached mindfulness.’ You can see your thoughts as just thoughts, and not as a reflection of reality. Most people think that when they think a thought, it must be true. For example, if I think that I’m stupid, this means I must be stupid. People strongly believe that their thoughts reflect reality.”
Patients who participated in the study have been pleasantly surprised by this form of treatment.
“The patients come in thinking they’re going to talk about all the problems they have and get to the bottom of it,” says Hagen, “but instead we try to find out how their mind and thinking processes work. You can’t control what you think, but you can control how you respond to what you think.”
The problem with several previous depression studies is that many of them did not use any control groups. Since depression often resolves itself over time, the lack of a control group makes it difficult to know whether a treatment was successful, or if the depression just naturally resolved itself.
NTNU’s study compared the MCT group against one that did not receive treatment, which strengthened the results of their study.
According to Hagen, a lot of mainstream depression treatment shows a high recurrence rate. Out of 100 patients, fully half relapse after a year, and after two years, 75 of the 100 have relapsed.
“The relapse rate in our study is much lower. Only a few per cent experienced a depressive relapse,” he says.
Could become the standard treatment
The University of Manchester in England has developed the metacognitive therapy approach over the past 20 years, as a form of cognitive therapy. Smaller studies at this university have shown that MCT treatment has had great efficacy in treating depression. A similar, soon-to-be-published study in Denmark has shown the same positive results.
Hagen hopes that metacognitive therapy will become the most common way to treat depression in Norway.
“When the national guidelines for the treatment of depression were changed five or six years ago,” Hagen says, “MCT had not been empirically tested.” Given the results of the NTNU and Danish studies, he recommends that professionals in the field consider whether this form of therapy should become the first choice for treating depression in people suffering from this mental disorder. “Many professionals in Norway have expertise in metacognitive therapy,” says Hagen.
Source: Roger Hagen – Norwegian University of Science and Technology
Image Source: NeuroscienceNews.com image is in the public domain.
Original Research: Full open access research for “Metacognitive Therapy for Depression in Adults: A Waiting List Randomized Controlled Trial with Six Months Follow-Up” by Roger Hagen, Odin Hjemdal, Stian Solem, Leif Edward Ottesen Kennair, Hans M. Nordahl, Peter Fisher and Adrian Wells in Frontiers in Psychology. Published online January 24 2017 doi:10.3389/fpsyg.2017.00031
Metacognitive Therapy for Depression in Adults: A Waiting List Randomized Controlled Trial with Six Months Follow-Up
This randomized controlled trial examines the efficacy of metacognitive therapy (MCT) for depression. Thirty-nine patients with depression were randomly assigned to immediate MCT (10 sessions) or a 10-week wait list period (WL). The WL-group received 10 sessions of MCT after the waiting period. Two participants dropped out from WL and none dropped out of immediate MCT treatment. Participants receiving MCT improved significantly more than the WL group. Large controlled effect sizes were observed for both depressive (d = 2.51) and anxious symptoms (d = 1.92). Approximately 70–80% could be classified as recovered at post-treatment and 6 months follow-up following immediate MCT, whilst 5% of the WL patients recovered during the waiting period. The results suggest that MCT is a promising treatment for depression. Future controlled studies should compare MCT with other active treatments.
“Metacognitive Therapy for Depression in Adults: A Waiting List Randomized Controlled Trial with Six Months Follow-Up” by Roger Hagen, Odin Hjemdal, Stian Solem, Leif Edward Ottesen Kennair, Hans M. Nordahl, Peter Fisher and Adrian Wells in Frontiers in Psychology. Published online January 24 2017 doi:10.3389/fpsyg.2017.00031